MARYAM NISA: Open Payments
NPI 1992284095 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,894 in 89 payments from 19 companies in 2025. Trend: 2023 $1,519 · 2024 $2,409 · 2025 $1,894
Food & beverage: $1,894
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $422 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $211 |
| GENZYME CORPORATION | 7 | $197 |
| Janssen Biotech, Inc. | 8 | $193 |
| Madrigal Pharmaceuticals | 9 | $170 |
| PFIZER INC. | 8 | $146 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $103 |
| Ardelyx, Inc. | 4 | $76 |
| Celltrion USA Inc. | 3 | $59 |
| Ipsen Biopharmaceuticals, Inc | 2 | $58 |
Products named: DUPIXENT, TREMFYA, ENTYVIO, REZDIFFRA, CREON, SKYRIZI, XIFAXAN, XELJANZ.
Industry payments across MD — which companies pay providers there.
